Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge
  • Policy / Pricing

What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge

KFF Medicare

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare Medicaid Services' (CMS) efforts to expand access and lower costs for GLP-1s through temporary demons

Metabolic & GLP-1

Read full story

pharminent May 11, 2026 (Last updated: May 15, 2026)

KFF Medicare

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary …

Metabolic & GLP-1

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: FDA Advances Drug Repurposing to Address Unmet Medical Needs
Next: Third Circuit Affirms Denial of Stelara Biosimilar Injunction

Related Stories

  • Policy / Pricing

US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028

pharminent July 22, 2026
  • Policy / Pricing

UK commits to pharma IP protection in Swiss trade deal

pharminent July 16, 2026
  • Policy / Pricing

Germany approves healthcare costs overhaul despite significant pharma opposition

pharminent July 13, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.